Search AWHL
Aspira Women's Health Inc.
OTC · CIK 926617
Last close0.23
Daily change+0.00 (0.00%)
10 Years gain-98.76%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AWHL · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
55.4Momentum
100.0Acceleration
100.0Confidence
76.0Annual Revenue16
Quarterly Revenue50
Annual CFO12
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.8 / 25
Quality19.3 / 25
Capital Efficiency20.0 / 20
Balance Sheet7.5 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 91.3949 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 2.218 percentage points.
Heavy share dilution · HIGHDiluted share count increased 104.9487%.
Key Metrics
Revenue Growth TTM-4.28%OK
Revenue CAGR 3Y4.04%OK
Gross Margin58.69%OK
Operating Margin-85.15%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y2,141.99%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y104.95%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $9.22M | $5.92M | -$7.91M | -$7.03M | -$7.05M | 64.18% | -85.86% | -76.44% | n/a | 34.1M |
| 2025 FY Dec 31, 2024 | $9.18M | $5.48M | -$16.28M | -$12.11M | -$12.15M | 59.67% | -177.28% | -132.32% | n/a | 14.13M |
| 2024 FY Dec 31, 2023 | $9.15M | $5.26M | -$18.85M | -$15.89M | -$15.92M | 57.48% | -205.94% | -173.89% | n/a | 9.23M |
| 2023 FY Dec 31, 2022 | $8.18M | $4.32M | -$31.14M | -$31.07M | -$31.30M | 52.82% | -380.47% | -382.45% | n/a | 7.77M |
| 2022 FY Dec 31, 2021 | $6.81M | $3.06M | -$32.60M | -$27.40M | -$27.58M | 44.95% | -478.49% | -404.86% | n/a | 7.41M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $8.72M | sum latest 4 fiscal quarters Revenue | OK | 0000926617-26-000054, 0000926617-25-000008 |
| Revenue Growth TTM | -4.28% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000926617-26-000054, 0000926617-25-000008 |
| Revenue CAGR 3Y | 4.04% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000926617-26-000020 |
| Revenue CAGR 5Y | 14.66% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000926617-26-000020 |
| Gross Profit CAGR 3Y | 11.02% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0000926617-26-000020 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000926617-26-000054, 0000926617-25-000008 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 58.69% | Gross Profit / Revenue | OK | 0000926617-26-000054, 0000926617-25-000008 |
| Operating Margin | -85.15% | Operating Income / Revenue | OK | 0000926617-26-000054, 0000926617-25-000008 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000926617-26-000054 |
| Current Ratio | 0.52x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.41x | (Cash + Short-term Investments) / Total Debt | OK | 0000926617-26-000054 |
| Revenue per Diluted Share | $0.20 | Revenue / Diluted Shares | OK | 0000926617-26-000054, 0000926617-25-000008 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |